Core Viewpoint - Lee's Pharmaceutical Holdings Limited (00950) reported a revenue of HKD 695 million for the six months ending June 30, 2025, representing a year-on-year increase of 5.5% [1] - The profit attributable to the company's owners was HKD 67.185 million, reflecting a year-on-year increase of 7.5% [1] - Earnings per share were HKD 0.1141, with an interim dividend proposed at HKD 0.022 per share [1] Revenue Growth Drivers - The revenue increase was primarily driven by strong sales performance across the company's product portfolio [1] - Notable growth was observed in rare disease and specialty products, with "Qufrile" injection achieving a robust growth of 31.4% and "Buleidining" rising by 12.9% [1] - In the traditional product mix of introduced products, "Fipril" saw a significant growth of 33.3%, regaining its position as the largest contributor after last year's transitional phase [1] Impact of Procurement Programs - The centralized procurement program played a crucial role in driving revenue growth, with "Sodium Dexamethasone Injection" and "Nacogdocevir Calcium Injection" recording growth rates of 18.8% and 11.3%, respectively [1] - The improved performance of these products supported overall revenue growth and helped offset the impact of sales slowdowns in several other products during the review period [1]

Group 1 - The core viewpoint of the article highlights the steady growth of Lee's Pharmaceutical Holdings Limited, with a revenue of HKD 695 million for the first half of 2025, representing a 5.5% increase compared to the same period last year [1] - The company's profit attributable to shareholders for the first half of 2025 was HKD 67.185 million, reflecting a year-on-year increase of 7.5%, indicating a sustainable growth trajectory and strengthened operational capabilities [1] - Earnings per share for the company stood at HKD 0.1141 [1] Group 2 - The company holds a 65% stake in its subsidiary, China Oncology Medical Limited (COF), which focuses on research and development in oncology, particularly in the field of immuno-oncology therapies [1] - COF has established a robust pipeline of oncology assets, including six innovative assets and four generic drugs, developed through a combination of internal research and licensing agreements [1] - In July 2025, the injection of Socazoli was approved by the National Medical Products Administration for a new indication, marking its second approved indication after initial conditional approval for the treatment of recurrent or metastatic cervical cancer [1]

智通财经APP讯，李氏大药厂(00950)发布截至2025年6月30日止6个月中期业绩，该集团取得收益6.95亿 港元，同比增加5.5%;公司拥有人应占溢利6718.5万港元，同比增加7.5%;每股盈利11.41港仙，拟派发中 期股息每股2.2港仙。 公告称，收益增加主要由本集团产品组合稳健的销售表现所带动。在各项罕见病及专科产品中，曲前列 尼尔注射液《芮旎尔®》取得31.4%的强劲增长，而《布累迪宁®》则上升12.9%。在引进产品的传统组 合中，《菲普利®》取得33.3%的显著增长，经去年的过渡阶段后再度成为贡献最大的产品。集中带量 采购(药品集采)计划下的产品在推动收益增长方面亦发挥重要作用，磺达肝癸钠注射液《立畅青®》及 那曲肝素钙注射液《立腾菁®》分别取得18.8%及11.3%的增长。此等产品表现改善为整体收益增长提供 支持，并有助抵销回顾期内若干其他产品销售放缓的影响。 ...

第 1 頁 共 2 頁 v 1.1.1 EF001 | 發行人所發行上市權證/可轉換債券的相關信息 | | | --- | --- | | 發行人所發行上市權證/可轉換債券 | 不適用 | | 其他信息 | | | 其他信息 | 不適用 | | 發行人董事 | | | 於本公佈日期，李小芳女士（主席）及李燁妮女士為執行董事；李小羿博士、James Charles Gale先生及黃瑞瑨先生為非執行董 | | | 事；而陳友正博士、蔣綺華女士及詹華強博士為獨立非執行董事。 | | EF001 第 2 頁 共 2 頁 v 1.1.1 免責聲明 | 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因 | | | --- | --- | | 公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 | | | 股票發行人現金股息公告 | | | 發行人名稱 | 李氏大藥廠控股有限公司 | | 股份代號 | 00950 | | 多櫃檯股份代號及貨幣 | 不適用 | | 相關股份代號及名稱 | 不適用 | | 公告標題 | 截至 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 佈 全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 Lee's Pharmaceutical Holdings Limited 李氏大藥廠控股有限公司 * （於開曼群島註冊成立之有限公司） （股份代號：950） 截至二零二五年六月三十日止六個月中期業績 財務摘要 | | | 截至六月三十日止六個月 | | | | --- | --- | --- | --- | --- | | | | 二零二五年 | 二零二四年 | 變 動 | | | | 千港元 | 千港元 | | | | 收 益 | 694,821 | 658,345 | +5.5% | | | 毛 利 | 360,053 | 350,595 | +2.7% | | 本公司擁有人應佔溢利 | | 67,185 | 62,478 | +7.5% | | | | 港 仙 | 港 仙 | | | | 每股盈利 | | | | | | 基 本 | 11. ...

| 表格序號 | 大股東/董事/最高行政人員名 作出披露的買入 / 費出或涉及的 每股的平均價 | | | 持有權益的股份數目 佔已發行的有關事件的日 相關法 | | --- | --- | --- | --- | --- | | | 股份數目 | | | 請參閱上述*註 有投票權股期(日/月/ 份權益 | | | | | | 份自分比 年) | | CS20250820E00127 | GL Capital Management GP 1201(L) | 2.053,500(L) | HKD 1.8958 | 40.036.500(L) 6.80(L)15/08/2025 | | | Limited | | | | | 股份代號: | Carles Concession Company of 00950 | | --- | --- | | 上市法國名稱: | 李氏大藥廠控股有限公 | | 日期 (日 / 月 / 年): | 21/07/2025 - 21/08/20 | 格隆汇8月21日丨根据联交所最新权益披露资料显示，2025年8月15日，李氏大药厂(00950.HK)遭GL Capital Manage ...

Group 1 - GL Capital Management GP Limited reduced its stake in Lee's Pharmaceutical Holdings Limited (00950) by 205.35 thousand shares at a price of HKD 1.8958 per share, totaling approximately HKD 3.893 million [1] - After the reduction, GL Capital Management's latest holding is 40.0365 million shares, representing a 6.8% ownership stake in the company [1]

Group 1 - GL Capital Management GP Limited reduced its stake in Lee's Pharmaceutical Holdings Limited (00950) by 2.0535 million shares at a price of HKD 1.8958 per share, totaling approximately HKD 3.893 million [1] - After the reduction, the latest shareholding number is 40.0365 million shares, representing a holding percentage of 6.8% [1]

香港联交所最新数据显示，8月8日，GL Capital Management GP Limited减持李氏大药厂(00950)127.65万 股，每股作价1.87港元，总金额约为238.71万港元。减持后最新持股数目为4703.5万股，持股比例为 7.99%。 ...

智通财经APP获悉，香港联交所最新数据显示，8月8日，GL Capital Management GP Limited减持李氏大 药厂(00950)127.65万股，每股作价1.87港元，总金额约为238.71万港元。减持后最新持股数目为4703.5 万股，持股比例为7.99%。 ...